New Treatment Options for Relapsed/Recurrent DLBCL: Impact on Sequencing Therapeutic Choices - Episode 16
Disparities in access to newer or expensive treatments, unmet needs in the treatment of DLBCL August 19, 2024
Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center , Elizabeth Budde, MD, PhD , Leo I. Gordon, MD, Robert H. Lurie Comprehensive Cancer Center , Frederick L. Locke, MD, Moffitt Cancer Center
A panel of experts discuss the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL.
Video content above is prompted by the following:
What are your thoughts on the current treatment landscape for bispecific antibodies and CAR T in R/R DLBCL, specifically related to sequencing and transplant eligibility?